专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150352118A1 EYE DROP COMPOSITION 审中-公开
标题翻译：眼睑组合物
公开(公告)号：US20150352118A1
公开(公告)日：2015-12-10
申请号：US14828365
申请日：2015-08-17
申请人： Nesya GORIS , Johan NEYTS , Erwin BLOMSMA , Stefaan WERA , Ainola BILLIET , Joeri AUWERX , Veerle DEBEURME , Maryline ROE , Pascal PUIG
发明人： Nesya GORIS , Johan NEYTS , Erwin BLOMSMA , Stefaan WERA , Ainola BILLIET , Joeri AUWERX , Veerle DEBEURME , Maryline ROE , Pascal PUIG
IPC分类号： A61K31/522 , A61K31/305 , A61K49/00 , A61K47/40
CPC分类号： A61K49/0004 , A61K9/0048 , A61K31/305 , A61K31/522 , A61K47/24 , A61K47/40
摘要： The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.
摘要翻译：本发明涉及包含2-氨基-9 - [[（1S，2R）-1,2-双（羟甲基）环丙基]甲基] -1,9-二氢-6H-嘌呤-6-酮的滴眼液组合物，一种用于诊断和治疗伴侣动物的疱疹性眼感染的用途。

2. 发明授权

US06893833B2 Identification of agents that increase glucose uptake 有权
标题翻译：识别增加葡萄糖摄取的药物
公开(公告)号：US06893833B2
公开(公告)日：2005-05-17
申请号：US10418036
申请日：2003-04-17
申请人： Alvar Grönberg , Per Wikström
发明人： Alvar Grönberg , Per Wikström
IPC分类号： C12N15/09 , A61K31/03 , A61K31/12 , A61K31/255 , A61K31/265 , A61K31/305 , A61K31/4164 , A61K31/44 , A61K45/00 , A61P3/10 , A61P43/00 , C12N5/06 , C12Q1/02 , C12Q1/26 , G01N33/66 , G01N33/68 , C12Q1/54
CPC分类号： A61K31/255 , A61K31/03 , A61K31/12 , A61K31/265 , A61K31/305 , A61K31/4164 , A61K31/44 , C12Q1/26 , G01N33/66 , G01N33/6893 , G01N2500/04 , G01N2800/042 , Y10S514/866
摘要： The present invention relates to the use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes. Specifically, the invention relates to a method for identifying an agent useful for the treatment or prophylaxis of a medical condition associated with elevated levels of blood glucose, the method comprising (i) contacting a candidate agent with a mammalian NAD(P)H oxidase or NAD(P)H oxidase complex; and (ii) determining whether said candidate agent inhibits the biological activities of the NAD(P)H oxidase or NAD(P)H oxidase complex.
摘要翻译：本发明涉及NAD（P）H氧化酶抑制剂用于增加葡萄糖的细胞摄取以及用于治疗和/或预防由胰岛素抵抗或其相关疾病引起的疾病，例如II型糖尿病。具体地，本发明涉及用于鉴定可用于治疗或预防与血糖水平升高相关的医学病症的药剂的方法，所述方法包括（i）使候选药剂与哺乳动物NAD（P）H氧化酶或 NAD（P）H氧化酶复合物; 和（ii）确定所述候选试剂是否抑制NAD（P）H氧化酶或NAD（P）H氧化酶复合物的生物活性。

3. 发明授权

US6071956A Treatment of tissues to reduce subsequent response to injury 有权
标题翻译：治疗组织以减少随后的损伤反应
公开(公告)号：US6071956A
公开(公告)日：2000-06-06
申请号：US158725
申请日：1998-09-23
申请人： Marvin J. Slepian , Stephen P. Massia
发明人： Marvin J. Slepian , Stephen P. Massia
IPC分类号： C07D311/30 , A61K31/35 , A61K31/352 , A61K33/00 , A61K33/24 , A61K38/00 , A61K41/00 , A61K45/00 , A61K47/48 , A61P7/02 , A61P43/00 , A01N55/06 , A61K31/305
CPC分类号： A61K41/0023
摘要： An exogenous stimulus is applied to tissues or cells which are at risk in a subsequent surgical procedure or other intervention which induces a response by the cells that minimizes reaction to the subsequent procedure. Stimuli can be chemical, physiological or physical. Examples include those stimuli known to induce expression of stress response proteins or heat shock proteins, especially heat shock protein 70 (hsp 70) and hsp 90, for example, exposure to heat or dilute hydrogen peroxide, or direct administration of exogenous heat shock proteins, or those stimuli which act to inhibit or reduce heat shock protein expression, for example, treatment with flavonoids. An amount effective to modulate levels of stress response proteins or reduce the endogenous response is administered, based on in vitro assays which are used to determine levels of heat shock proteins or which are experimentally determined to reduce cell proliferation, thrombus formation, and matrix deposition following subsequent exposure to a procedure. Procedures can be surgery, angioplasty, or abrasion. The method and compositions are also useful in mediating some disease processes, where the process involves undesirable migration.
摘要翻译：外源刺激被应用于随后的外科手术或其它干预中处于风险中的组织或细胞，其诱导细胞的反应使得对后续过程的反应最小化。刺激可以是化学，生理或物理。实例包括已知诱导应激反应蛋白或热休克蛋白表达的刺激物，特别是热休克蛋白70（hsp70）和hsp90，例如暴露于热或稀释过氧化氢，或直接施用外源热休克蛋白，或用于抑制或减少热休克蛋白表达的那些刺激物，例如用类黄酮治疗。基于用于测定热休克蛋白水平或经实验确定以减少细胞增殖，血栓形成和基质沉积的体外测定，施用有效调节应激反应蛋白水平或降低内源性应答的量随后接触一个程序。手术可以是手术，血管成形术或磨损。该方法和组合物也可用于介导某些疾病过程，其中该过程涉及不期望的迁移。

4. 发明授权

US5744452A .gamma.-L-glutamyl containing immunomodulator compounds and methods therewith 失效
标题翻译：含有γ-L-谷氨酰的免疫调节剂化合物及其方法
公开(公告)号：US5744452A
公开(公告)日：1998-04-28
申请号：US634718
申请日：1996-04-18
申请人： Alexander A. Kolobov , Andrey S. Simbirtsev , Sergey V. Kulikov , Alexey N. Prusakov , Natalia M. Kalinina , Natalia V. Pigareva , Alexander U. Kotov , Vladimir M. Shpen , Oleg A. Kaurov , Sergey A. Ketlinsky
发明人： Alexander A. Kolobov , Andrey S. Simbirtsev , Sergey V. Kulikov , Alexey N. Prusakov , Natalia M. Kalinina , Natalia V. Pigareva , Alexander U. Kotov , Vladimir M. Shpen , Oleg A. Kaurov , Sergey A. Ketlinsky
IPC分类号： A61K31/305 , A61K31/381 , C07D209/20 , C07D333/22 , A61K38/00 , A61K31/38 , A61K31/40
CPC分类号： C07D333/22 , A61K31/305 , A61K31/381 , C07D209/20
摘要： The new class of synthetic immunomodulatory molecules having a .gamma.-L-glutamyl- moiety at the amino terminus are provided as illustrated by Formula 1. ##STR1## In Formula 1, the Greek symbols designate the noted carbon atoms, R is hydrogen, acyl or alkyl, and X is an aromatic or heterocyclic amino acid or its derivative. Included as members of the new class (in addition to Bestim, .gamma.-L-glutamyl-L-tryptophan) are those compounds where R=hydrogen and X=L-tryptophan, such as .gamma.-L-glutamyl-N.sub.in -formyl-L-tryptophan, N-methyl-.gamma.-L-glutamyl-L-tryptophan, N-acetyl-.gamma.-L-glutamyl-L-tryptophan, and .gamma.-L-glutamyl-.beta.-thienyl-D-alanylamide. A preferred embodiment, termed "BESTIM," has the chemical structure of .gamma.-L-glutamyl-L-tryptophan.
摘要翻译：提供了在氨基末端具有γ-L-谷氨酰基部分的新一类合成免疫调节分子，如式1所示。式1中，希腊符号表示所述碳原子，R为氢，酰基或烷基，X是芳族或杂环氨基酸或其衍生物。作为新类的成员（除了Bestim，γ-L-谷氨酰-L-色氨酸之外）包括R =氢和X = L-色氨酸的那些化合物，例如γ--L-谷氨酰 - in - 甲酰基-L 色氨酸，N-甲基-γ-L-谷氨酰-L-色氨酸，N-乙酰基-γ-L-谷氨酰-L-色氨酸和γ--L-谷氨酰基-β-噻吩基-D-丙氨酰胺。称为“BESTIM”的优选实施方案具有γ-L-谷氨酰-L-色氨酸的化学结构。

5. 发明授权

US5567724A Alkaline and acid phosphatase inhibitors in treatment of neurological disorders 失效
标题翻译：碱性和酸性磷酸酶抑制剂治疗神经系统疾病
公开(公告)号：US5567724A
公开(公告)日：1996-10-22
申请号：US252109
申请日：1994-06-01
申请人： Judith A. Kelleher , David D. Eveleth
发明人： Judith A. Kelleher , David D. Eveleth
IPC分类号： C07D513/04 , A61K31/00 , A61K31/19 , A61K31/305 , A61K31/425 , A61K33/00 , A61K33/16 , A61K45/00 , A61P25/28 , A61P43/00 , A61K31/38
CPC分类号： A61K31/19 , A61K31/00 , A61K31/305 , A61K31/425 , A61K33/00 , A61K33/16
摘要： The present invention provides a method of inhibiting .beta.-amyloid toxicity in brain cells. The method includes administering to the cells an amount of an alkaline phosphatase inhibitor which is pharmacologically effective to reduce degeneration in the cells. Methods of treatment of peripheral neuropathy are also provided using acid or alkaline phosphatase inhibitors.
摘要翻译：本发明提供抑制脑细胞中β-淀粉样蛋白毒性的方法。该方法包括向细胞施用一定量的碱性磷酸酶抑制剂，其在药理学上有效以减少细胞的变性。使用酸或碱性磷酸酶抑制剂也可提供治疗周围神经病变的方法。

6. 发明授权

US5516765A Therapeutic method for the treatment or prevention of snoring 失效
标题翻译：治疗或预防打鼾的治疗方法
公开(公告)号：US5516765A
公开(公告)日：1996-05-14
申请号：US359342
申请日：1994-12-19
申请人： Guy Andermann
发明人： Guy Andermann
IPC分类号： A61K31/305 , A61K31/70 , A61K31/715 , A61K36/00 , A61K36/35 , A61K36/42 , A61K36/81
CPC分类号： A61K31/715 , A61K36/35 , A61K36/42 , A61K36/81
摘要： This new solution according to the invention, contains mucopolysaccharides of the glycosaminoglycane type as principle active agent, and more precisely sodic chondroitin sulphate. The excipient of this composition contains at least one mercury preserving agent, one substance with isotonic properties, and a phosphate buffer. The principle active agent may be combined with plant or mineral compounds, or with homeopathic or allopathic concentrations which synergise its therapeutic activities.
摘要翻译：根据本发明的这种新的溶液含有作为主要活性剂的糖胺聚糖类型的粘多糖，更准确地说是硫酸软骨素。该组合物的赋形剂含有至少一种汞防腐剂，一种具有等渗性质的物质和磷酸盐缓冲剂。主要的活性剂可以与植物或矿物质化合物组合，或者与其治疗活性协同作用的顺势疗法或抗病毒浓度组合。

7. 发明授权

US4469868A Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines 失效
标题翻译：烷基咪唑并[1,2-c]吡唑并[3,4-e]嘧啶
公开(公告)号：US4469868A
公开(公告)日：1984-09-04
申请号：US381484
申请日：1982-05-24
申请人： Horace A. DeWald
发明人： Horace A. DeWald
IPC分类号： A61K31/505 , A61P25/18 , C07D231/14 , C07D231/16 , C07D231/38 , C07D231/40 , C07D403/04 , C07D487/04 , C07D487/14 , A61K31/305
CPC分类号： C07D231/38 , C07D231/14 , C07D231/16 , C07D231/40 , C07D403/04 , C07D487/04 , C07D487/14
摘要： Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines and pharmaceutically acceptable salts are described. These compounds are antipsychotic agents. Methods for their preparation, pharmaceutical compositions which contain them and methods for using said compositions are also described.
摘要翻译：描述了烷基咪唑并[1,2-c]吡唑并[3,4-e]嘧啶及其药学上可接受的盐。这些化合物是抗精神病药。还描述了它们的制备方法，含有它们的药物组合物和使用所述组合物的方法。

8. 发明授权

US4443429A Contact lens disinfecting and preserving solution (polymeric) 失效
标题翻译：隐形眼镜消毒和保存溶液（聚合物）
公开(公告)号：US4443429A
公开(公告)日：1984-04-17
申请号：US418351
申请日：1982-09-15
申请人： Francis X. Smith , Thomas M. Riedhammer
发明人： Francis X. Smith , Thomas M. Riedhammer
IPC分类号： A01N33/12 , A61L12/14 , A61K31/74 , A61K31/14 , A61K31/19 , A61K31/305
CPC分类号： A01N33/12 , A61L12/145 , Y10S514/839
摘要： A disinfecting and/or preserving solution for contact lenses is disclosed. The disinfecting solution is an aqueous solution containing 0.00001 to 0.1 weight percent of a dimethyldiallylammonium chloride homopolymer having a molecular weight from about 10,000 to about 1,000,000, optionally together with up to 0.5 weight percent of ethylenediaminetetraacetic acid or other enhancers and optional buffers and the like.
摘要翻译：公开了用于隐形眼镜的消毒和/或保存溶液。消毒溶液是含有0.00001至0.1重量％的分子量为约10,000至约1,000,000的二甲基二烯丙基氯化铵均聚物，任选地与至多0.5重量％的乙二胺四乙酸或其它增强剂和任选的缓冲剂等的水溶液。

9. 发明授权

US4076816A Antibiotic mixture 失效
标题翻译：抗生素混合物
公开(公告)号：US4076816A
公开(公告)日：1978-02-28
申请号：US573453
申请日：1975-05-01
申请人： Leif Tybring
发明人： Leif Tybring
IPC分类号： A61K31/43 , A61K31/505 , C07D499/00 , A61K31/305
CPC分类号： A61K31/43 , A61K31/505 , C07D499/00
摘要： The present invention relates to a new pharmaceutical composition with synergistic properties, to dosage units thereof, and to the use of the said composition and dosage units in the human or veterinary practice for the treatment of patients suffering from infectious diseases. The composition contains as active ingredients an amidinopenicillanic acid derivative of the formula ##STR1## in which R is hydrogen or a lower alkanoyloxymethyl radical including the pivaloyloxymethyl radical or atoxic salts thereof in combination with 2,4-diamino-5(3,4,5-trimethoxybenzyl)-pyrimidine, also known under the name trimethoprim, used hereinafter, or atoxic salts thereof.
摘要翻译：本发明涉及具有协同性质的新药物组合物，其剂量单位，以及人或兽医实践中所述组合物和剂量单位用于治疗患有感染性疾病的患者的用途。该组合物含有作为活性成分的式Ⅰ“ι”的脒基青霉烷酸衍生物，其中R是氢或含有新戊酰氧基甲基或其无毒盐的低级烷酰氧基甲基与2,4-二氨基-5（3,4， 5-三甲氧基苄基） - 嘧啶，也称为甲氧苄氨嘧啶，以下使用，或其无毒盐。

10. 发明申请

US20210290588A1 USE OF gTso thal IN MANUFACTURING MEDICAMENT FOR PROMOTION OF MS-275 TO CROSS BLOOD-BRAIN BARRIER 有权
公开(公告)号：US20210290588A1
公开(公告)日：2021-09-23
申请号：US16987800
申请日：2020-08-07
申请人： Northwest Institute of Plateau Biology, Chinese Academy of Sciences
发明人： Xiaohui ZHAO , Ting ZHANG , Huilan YUE , Jihong TAO , Wenjing JIA , Guoying ZHOU , Lixin WEI , Chen CHEN
IPC分类号： A61K31/305 , A61K47/38 , A61K47/26 , A61K47/12 , A61K31/4406
摘要： The present invention relates to use of gTso thal in manufacturing a medicament for the promotion of MS-275 to cross the blood-brain barrier (BBB), and belongs to the technical field of pharmaceutical preparation. Administration of the medicament manufactured by the use of the present invention in combination with MS-275 significantly increases MS-275 to cross the BBB into the brain tissue, and prominently promotes the accumulation of the medicament therein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式